Serenoa repens monotherapy for benign prostatic hyperplasia (BPH): An updated Cochrane systematic review

BJU International

Volumn 109, Issue 12, 2012, Pages 1756-1761

  MacDonald, Roderick ^a   Tacklind, James W ^a   Rutks, Indulis ^a   Wilt, Timothy J ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

benign prostatic hyperplasia; phytotherapy; Serenoa repens; systematic review

Indexed keywords

PLACEBO; SABAL EXTRACT;

CAUCASIAN; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FLOW RATE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG TERM CARE; LOWER URINARY TRACT SYMPTOM; MONOTHERAPY; NOCTURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; REVIEW; SCORING SYSTEM; SYSTEMATIC REVIEW; UPPER RESPIRATORY TRACT INFECTION; URODYNAMICS;

HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; PROSTATIC HYPERPLASIA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SERENOA; TREATMENT OUTCOME;

EID: 84861577046     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11172.x     Document Type: Review

References (32)

1. Di Silverio F, Flammia GP, Sciarra A, et al,. Plant extracts in benign prostatic hyperplasia. Minerva Urol Nefrol 1993; 45: 143-9
2. Buck AC,. Phytotherapy for the prostate. Br J Urol 1996; 78: 325-6
3. Barnes PM, Powell-Griner E, McFann K, Nahin RL,. Complementary and alternative medicine use among adults: United States, 2002. Adv Data 2004; 343: 1-19
4. Bales G, Christiano AP, Kirsh E, Gerber GS,. Phytotherapeutic agents in the treatment of lower urinary tract symptoms: a demographic analysis of awareness and use at the University of Chicago. Urology 1999; 54: 86-9
5. Tacklind J, MacDonald R, Rutks I, Wilt TJ,. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009; (2): CD001423. DOI: 10.1002/14651858.CD001423.pub2
6. Schulz KF, Chalmers I, Hayes RJ, Altman DG,. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-12
7. Higgins JP, Altman DG, Stern JA,. Assessing risk of bias in included studies. In, Higgins JP, Green S, eds, Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 [updated March 2011], Chapter 8. The Cochrane Collaboration; Available at. Accessed 4 March 2011
8. Review Manager (RevMan). [Computer program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011
9. Higgins JP, Thompson SG, Deeks JJ, Altman DG,. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-60
10. Barry MJ, Meleth S, Lee JY, et al,. Effect of increasing doses of Saw palmetto extract on lower urinary tract symptoms. JAMA 2011; 306: 1344-51
11. Bauer HW, Casarosa C, Cosci M, Fratta M, Blessmann G,. Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study. MMW Fortschr Med 1999; 141: 127-32
12. Bent S, Kane C, Shinohara K, et al,. Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006; 354: 557-66
13. Boccafoschi C, Annoscia S,. Confronto fra estratto di Serenoa repens e placebo mediate prova clinica controllata in pazienti con adenomatosi prostatica. Urologia 1983; 50: 1257-68
14. Braeckman J, Denis L, de Lavel J, et al,. A double-blind, placebo-controlled study of the plant extract Serenoa repens in the treatment of benign hyperplasia of the prostate. Eur J Clin Res 1997; 9: 247-59
15. Champault G, Patel JC, Bonnard AM,. A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 1984; 18: 461-2
16. Cukier J, Ducassou J, Le Guillou M, Leriche A, Lobel B, Toubol J,. Permixon versus placebo; resultats d'une 'etude multicentrique. C R Ther Pharmacol Clin 1985; 4: 15-21
17. Descotes JL, Rambeaud JJ, Deschaseaux P, Faure G,. Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after the exclusion of placebo responders. Clin Drug Investig 1995; 5: 291-7
18. Emili E, Lo Cigno M, Petrone U,. Risultati clinici su un nuovo farmaco nella terapia dell'ipertofia della prostata (Permixon). Urologia 1983; 50: 1042-8
19. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD,. Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001; 58: 960-4
20. Löbelenz J,. Extractum Sabal fructus bei benigner prostatahyperplasie (BPH). klinische prufung im stadium I und II. Therapeutikon 1992; 6: 34-7
21. Mandressi S, Tarallo U, Maggioni A, Tombolini P, Rocco F, Quadraccia S,. Terapia medica dell'adenoma prostatico: confronto della efficacia dell'estratto di Serenoa Repens (Permixon®) versus l'estratto di Pigeum Africanum e placebo. Valutazione in doppio cieco. Urologia 1983; 50: 752-8
22. Mattei FM, Capone M, Acconcia A,. Medikamentose therapie der benignen prostatahyperplasie mit einem extrakt der sagepalme. TW Urol Nephrol 1990; 2: 346-50
23. Mohanty NK, Jha RJ, Dutt C,. Randomized double-blind controlled clinical trial of Serenoa repens versus placebo in the management of patients with symptomatic Grade I to Grade II benign prostatic hyperplasia (PBH). Indian J Urol 1999; 16: 26-31
24. Reece Smith H, Memon A, Smart CJ, Dewbury K,. The value of Permixon in benign prostatic hypertrophy. Br J Urol 1986; 58: 36-40
25. Tasca A, Barulli M, Cavazzana A, Zattoni F, Artibani W, Pagano F,. Trattamento della sintomatologia ostruttiva da adenoma prostatico con estratto di Serenoa repens. Studio clinico in doppio cieco. Minerva Urol Nefrol 1985; 37: 87-91
26. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA,. Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003; 92: 267-70
27. Wilt TJ, Ishani A, Stark G, et al,. Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2000; (2): CD001423. DOI: 10.1002/14651858.CD001423
28. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C,. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998; 280: 1604-9
29. Habib FK, Wyllie MG,. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004; 7: 195-200
30. Lowe FC, Ku JC,. Phytotherapy in treatment of benign prostatic hyperplasia: a critical review. Urology 1996; 48: 12-20
31. Boyle P, Robertson C, Lowe F, Roehrborn C,. Updated meta-analysis of clinical trials of Serenoa repens extract in the treatment of symptomatic benign prostatic hyperplasia. BJU Int 2004; 93: 751-6
32. Maccagnano C, Salonia A, Briganti A, et al,. A critical analysis of Permixon™ in the treatment of lower urinary tract symptoms due to benign prostatic enlargement. Eur Urol Suppl 2006; 5: 430-40